FourThought Financial Partners LLC Grows Holdings in Insulet Co. (NASDAQ:PODD)

FourThought Financial Partners LLC boosted its position in Insulet Co. (NASDAQ:PODD) by 1.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,461 shares of the medical instruments supplier’s stock after buying an additional 61 shares during the quarter. FourThought Financial Partners LLC’s holdings in Insulet were worth $968,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PODD. Qube Research & Technologies Ltd lifted its stake in shares of Insulet by 227.3% in the third quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier’s stock worth $61,673,000 after acquiring an additional 268,553 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Insulet by 119.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 79,375 shares of the medical instruments supplier’s stock worth $17,223,000 after purchasing an additional 43,147 shares during the last quarter. Asset Management One Co. Ltd. raised its position in shares of Insulet by 33.7% in the 4th quarter. Asset Management One Co. Ltd. now owns 36,677 shares of the medical instruments supplier’s stock valued at $8,048,000 after purchasing an additional 9,240 shares in the last quarter. Graham Capital Management L.P. boosted its stake in shares of Insulet by 689.8% during the 3rd quarter. Graham Capital Management L.P. now owns 23,095 shares of the medical instruments supplier’s stock valued at $3,683,000 after buying an additional 20,171 shares during the last quarter. Finally, Aquila Investment Management LLC acquired a new stake in shares of Insulet during the fourth quarter worth approximately $1,302,000.

Insider Buying and Selling at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the sale, the director now directly owns 2,567 shares in the company, valued at $418,215.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.47% of the stock is owned by corporate insiders.

Insulet Stock Performance

Shares of Insulet stock traded up $1.01 during trading on Friday, hitting $174.43. 614,615 shares of the stock were exchanged, compared to its average volume of 712,105. The stock has a market cap of $12.21 billion, a PE ratio of 59.94, a P/E/G ratio of 3.14 and a beta of 1.00. The stock’s fifty day moving average is $169.57 and its 200 day moving average is $180.95. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $335.91. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. During the same quarter in the previous year, the business earned $0.55 EPS. The firm’s revenue for the quarter was up 37.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Insulet Co. will post 3.08 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on PODD shares. Piper Sandler decreased their price objective on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. JPMorgan Chase & Co. upped their price objective on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Stifel Nicolaus lifted their target price on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Finally, Barclays dropped their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average price target of $243.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.